Next Article in Journal
Natural Pigments of Bacterial Origin and Their Possible Biomedical Applications
Next Article in Special Issue
Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project
Previous Article in Journal
Root Caries Preventive Effect of Varnishes Containing Fluoride or Fluoride + Chlorhexidine/Cetylpyridinium Chloride In Vitro
Previous Article in Special Issue
Changes in Invasive Pneumococcal Disease Caused by Streptococcus pneumoniae Serotype 1 following Introduction of PCV10 and PCV13: Findings from the PSERENADE Project
microorganisms-logo
Article Menu

Article Menu

Printed Edition

A printed edition of this Special Issue is available at MDPI Books....
Article

Serotype Distribution of Remaining Pneumococcal Meningitis in the Mature PCV10/13 Period: Findings from the PSERENADE Project

1
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
2
Independent Consultant, 1296 Coppet, Switzerland
3
World Health Organization, 1202 Geneva, Switzerland
4
Center of Bacteriology, National Laboratory for Meningitis and Pneumococcal Infections, Institute Adolfo Lutz (IAL), São Paulo 01246-902, Brazil
5
Department of Pediatrics, Division of Pediatric Infectious Diseases, University of Utah Health Sciences Center, Salt Lake City, UT 84132, USA
6
National Centre for Infectious Diseases, National Public Health Laboratory, Singapore 308442, Singapore
7
Malawi-Liverpool-Wellcome Trust Clinical Research Programme, P.O. Box 30096, Chichiri, Blantyre 3, Malawi
8
National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Arctic Investigations Program, Division of Preparedness and Emerging Infections, Anchorage, AK 99508, USA
9
Department of Infectious Diseases, Italian National Institute of Health (Istituto Superiore di Sanità, ISS), 00161 Rome, Italy
10
Instituto Costarricense de Investigación y Enseñanza en Nutrición y Salud, Tres Ríos, 30301 Cartago, Costa Rica
11
CIBER Epidemiología y Salud Pública, (CIBERESP), 28029 Madrid, Spain
12
Surveillance and Public Health Emergency Response, Public Health Agency of Catalonia, 08005 Barcelona, Spain
13
Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, 2192 Johannesburg, South Africa
14
School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, 2000 Johannesburg, South Africa
15
Irish Meningitis and Sepsis Reference Laboratory, Children’s Health Ireland at Temple Street, Temple Street, D01 YC76 Dublin 1, Ireland
16
Distinguished Professor of Pediatrics and Infectious Diseases, The Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
17
Department of Social and Preventive Medicine, Laval University, Québec, QC G1V 0A6, Canada
18
Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium
19
National Reference Centre for Streptococcus Pneumoniae, University Hospitals Leuven, 3000 Leuven, Belgium
20
Faculty of Sciences and Health Techniques, Mohammed VI University of Health Sciences (UM6SS) of Casablanca, 20250 Casablanca, Morocco
21
National Reference Laboratory, Mohammed VI University of Health Sciences (UM6SS), 82403 Casablanca, Morocco
22
National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
23
Instituto de Salud Pública de Navarra—IdiSNA, 31003 Pamplona, Spain
24
Swiss National Reference Centre for Invasive Pneumococci, Institute for Infectious Diseases, University of Bern, 3012 Bern, Switzerland
25
Department of Microbiology and Carol Yu Centre for Infection, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
26
National Centre for Immunisation Research and Surveillance and Discipline of Child and Adolescent Health, Faculty of Medicine and Health, Children’s Hospital Westmead Clinical School, University of Sydney, Westmead, NSW 2145, Australia
27
Department of Clinical Microbiology, Landspitali—The National University Hospital, Hringbraut, 101 Reykjavik, Iceland
28
Immunisation and Countermeasures Division, Public Health England, London NW9 5EQ, UK
29
Toronto Invasive Bacterial Diseases Network, and Department of Laboratory, Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada
30
World Health Organization Regional Office for Africa, P.O. Box 06, Brazzaville, Congo
31
Department of Health Security, Finnish Institute for Health and Welfare, 00271 Helsinki, Finland
32
Health Sciences Unit, Faculty of Social Sciences, Tampere University, 33100 Tampere, Finland
33
Toyama Institute of Health, Imizu, Toyama 939-0363, Japan
34
Department of Pediatrics, University of Calgary, Calgary, AB T3B 6A8, Canada
35
Laboratorio Regional de Salud Pública, Dirección General de Salud Pública, Comunidad de Madrid, 28053 Madrid, Spain
36
Centre for Disease Prevention and Control of Latvia, 1005 Riga, Latvia
37
Doctoral Studies Department, Riga Stradinš University, 1007 Riga, Latvia
38
Department of Medical Microbiology, Faculty of Medicine, Medical University of Sofia, 1431 Sofia, Bulgaria
39
Bacterial Respiratory Infection Service, Scottish Microbiology Reference Laboratory, NHS GG&C, Glasgow G4 0SF, UK
40
College of Medical, Veterinary & Life Sciences, Glasgow Dental Hospital & School, University of Glasgow, Glasgow G2 3JZ, UK
41
Infectious Disease Epidemiology and Prevention, Statens Serum Institut, DK-2300 Copenhagen S, Denmark
42
Department of Public Health and Epidemiology, Faculty of Medicine, Universidad de Los Andes, 12455 Santiago, Chile
43
National Reference Center for Streptococci, Department of Medical Microbiology, University Hospital RWTH Aachen, 52074 Aachen, Germany
44
Medical Microbiology and Infection Prevention, Netherlands Reference Laboratory for Bacterial Meningitis, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
45
National Reference Centre for Pneumococci, Centre Hospitalier Intercommunal de Créteil, 94000 Créteil, France
46
Department of Infection Control and Vaccine, Norwegian Institute of Public Health, 0456 Oslo, Norway
47
Department of Pediatrics, Yale New Haven Children’s Hospital, New Haven, CT 06504, USA
48
Servicio de Bacteriología Clínica, Departamento de Bacteriología, INEI—ANLIS “Dr. Carlos G. Malbrán”, C1282 AFF Buenos Aires, Argentina
*
Authors to whom correspondence should be addressed.
Present address: Pfizer, Inc. Collegeville, PA 19426, USA. Affiliation at the time this work was completed was Johns Hopkins Bloomberg School of Public Health.
Present address: Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. Affiliation at the time this work was completed was World Health Organization.
§
Members are listed in the Appendix ATable A1.
Academic Editor: James Stuart
Microorganisms 2021, 9(4), 738; https://doi.org/10.3390/microorganisms9040738
Received: 4 March 2021 / Revised: 26 March 2021 / Accepted: 28 March 2021 / Published: 1 April 2021
(This article belongs to the Special Issue Bacterial Meningitis: Epidemiology and Vaccination)
Pneumococcal conjugate vaccine (PCV) introduction has reduced pneumococcal meningitis incidence. The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project described the serotype distribution of remaining pneumococcal meningitis in countries using PCV10/13 for least 5–7 years with primary series uptake above 70%. The distribution was estimated using a multinomial Dirichlet regression model, stratified by PCV product and age. In PCV10-using sites (N = 8; cases = 1141), PCV10 types caused 5% of cases <5 years of age and 15% among ≥5 years; the top serotypes were 19A, 6C, and 3, together causing 42% of cases <5 years and 37% ≥5 years. In PCV13-using sites (N = 32; cases = 4503), PCV13 types caused 14% in <5 and 26% in ≥5 years; 4% and 13%, respectively, were serotype 3. Among the top serotypes are five (15BC, 8, 12F, 10A, and 22F) included in higher-valency PCVs under evaluation. Other top serotypes (24F, 23B, and 23A) are not in any known investigational product. In countries with mature vaccination programs, the proportion of pneumococcal meningitis caused by vaccine-in-use serotypes is lower (≤26% across all ages) than pre-PCV (≥70% in children). Higher-valency PCVs under evaluation target over half of remaining pneumococcal meningitis cases, but questions remain regarding generalizability to the African meningitis belt where additional data are needed. View Full-Text
Keywords: pneumococcal meningitis; serotype distribution; PCV impact; global; meta-analysis pneumococcal meningitis; serotype distribution; PCV impact; global; meta-analysis
Show Figures

Figure 1

MDPI and ACS Style

Garcia Quesada, M.; Yang, Y.; Bennett, J.C.; Hayford, K.; Zeger, S.L.; Feikin, D.R.; Peterson, M.E.; Cohen, A.L.; Almeida, S.C.G.; Ampofo, K.; Ang, M.; Bar-Zeev, N.; Bruce, M.G.; Camilli, R.; Chanto Chacón, G.; Ciruela, P.; Cohen, C.; Corcoran, M.; Dagan, R.; De Wals, P.; Desmet, S.; Diawara, I.; Gierke, R.; Guevara, M.; Hammitt, L.L.; Hilty, M.; Ho, P.-L.; Jayasinghe, S.; Kleynhans, J.; Kristinsson, K.G.; Ladhani, S.N.; McGeer, A.; Mwenda, J.M.; Nuorti, J.P.; Oishi, K.; Ricketson, L.J.; Sanz, J.C.; Savrasova, L.; Setchanova, L.P.; Smith, A.; Valentiner-Branth, P.; Valenzuela, M.T.; van der Linden, M.; van Sorge, N.M.; Varon, E.; Winje, B.A.; Yildirim, I.; Zintgraff, J.; Knoll, M.D.; the PSERENADE Team. Serotype Distribution of Remaining Pneumococcal Meningitis in the Mature PCV10/13 Period: Findings from the PSERENADE Project. Microorganisms 2021, 9, 738. https://doi.org/10.3390/microorganisms9040738

AMA Style

Garcia Quesada M, Yang Y, Bennett JC, Hayford K, Zeger SL, Feikin DR, Peterson ME, Cohen AL, Almeida SCG, Ampofo K, Ang M, Bar-Zeev N, Bruce MG, Camilli R, Chanto Chacón G, Ciruela P, Cohen C, Corcoran M, Dagan R, De Wals P, Desmet S, Diawara I, Gierke R, Guevara M, Hammitt LL, Hilty M, Ho P-L, Jayasinghe S, Kleynhans J, Kristinsson KG, Ladhani SN, McGeer A, Mwenda JM, Nuorti JP, Oishi K, Ricketson LJ, Sanz JC, Savrasova L, Setchanova LP, Smith A, Valentiner-Branth P, Valenzuela MT, van der Linden M, van Sorge NM, Varon E, Winje BA, Yildirim I, Zintgraff J, Knoll MD, the PSERENADE Team. Serotype Distribution of Remaining Pneumococcal Meningitis in the Mature PCV10/13 Period: Findings from the PSERENADE Project. Microorganisms. 2021; 9(4):738. https://doi.org/10.3390/microorganisms9040738

Chicago/Turabian Style

Garcia Quesada, Maria, Yangyupei Yang, Julia C. Bennett, Kyla Hayford, Scott L. Zeger, Daniel R. Feikin, Meagan E. Peterson, Adam L. Cohen, Samanta C.G. Almeida, Krow Ampofo, Michelle Ang, Naor Bar-Zeev, Michael G. Bruce, Romina Camilli, Grettel Chanto Chacón, Pilar Ciruela, Cheryl Cohen, Mary Corcoran, Ron Dagan, Philippe De Wals, Stefanie Desmet, Idrissa Diawara, Ryan Gierke, Marcela Guevara, Laura L. Hammitt, Markus Hilty, Pak-Leung Ho, Sanjay Jayasinghe, Jackie Kleynhans, Karl G. Kristinsson, Shamez N. Ladhani, Allison McGeer, Jason M. Mwenda, J. P. Nuorti, Kazunori Oishi, Leah J. Ricketson, Juan C. Sanz, Larisa Savrasova, Lena P. Setchanova, Andrew Smith, Palle Valentiner-Branth, Maria T. Valenzuela, Mark van der Linden, Nina M. van Sorge, Emmanuelle Varon, Brita A. Winje, Inci Yildirim, Jonathan Zintgraff, Maria D. Knoll, and the PSERENADE Team. 2021. "Serotype Distribution of Remaining Pneumococcal Meningitis in the Mature PCV10/13 Period: Findings from the PSERENADE Project" Microorganisms 9, no. 4: 738. https://doi.org/10.3390/microorganisms9040738

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop